Relaxin-3/RXFP3 networks: an emerging target for the treatment of depression and other neuropsychiatric diseases?
Animal and clinical studies of gene-environment interactions have helped elucidate the mechanisms involved in the pathophysiology of several mental illnesses including anxiety, depression and schizophrenia; and have led to the discovery of improved treatments.The study of neuropeptides and their receptors is a parallel frontier of neuropsychopharma